Macro investor Jordy Visser stated that quantum computing poses no immediate threat to Bitcoin due to hardware limitations, with estimates suggesting 20 to 40 years before it becomes a serious risk. He highlighted that AI-driven cyberattacks, especially password attacks by AI agents, are a more urgent security concern. Visser emphasized the need for the Bitcoin community and financial institutions, increasingly involved in crypto infrastructure, to collaborate on cryptographic security solutions. His remarks suggest there is time to prepare for quantum threats, but immediate focus should be on combating AI-enhanced cyber vulnerabilities.
Bitcoin quantum threat timing provides context for cryptocurrency market activity. For readers following major cryptocurrencies on Pluang, here is the market snapshot as of Oct 24, 2026 21:01 WIB: out of 50 priced major cryptocurrencies, 5 rose and 43 fell today. Notable movers include BAL (Balancer) up 11.14% at Rp16.297, EOS (EOS.IO) up 8.13% at Rp12.649, and SXP (Solar) down 46.27% at Rp37, with typical hold times ranging from 85 to 94 days.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
